In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019.
According to poll results from Pew Research Center, the American public is accepting of gene editing in animals that could benefit human health, potentially removing a barrier to research, as noted by a pharma analyst at GlobalData.
Earlier this month (9 August) we passed the six-month time point before all companies in Europe will be expected to comply with the falsified medicines directive (FMD).
The US Food and Drug Administration (FDA) has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Here, Dr Sheuli Porkess, deputy chief scientific officer, Association of the British Pharmaceutical Industry (ABPI), outlines how the pharmaceutical industry takes a substance from molecule to medicine and how the process requires persistence.
In the latest annual snapshot of the manufacturing industry — published by the manufacturers’ organisation, EEF, and Santander — it has been shown that the sector contributes more than just the sum of its part.
In this online exclusive, Erik Janssen, vice president of Global New Patient Solutions Neurology at UCB, talks about why advancements in big data and analytics might be the key to helping patients with epilepsy.
The recent collaboration between Merck and InnoCore Pharmaceuticals for the development of a new drug delivery platform that will improve compliance could be a step forward in the delivery of biologics, according to GlobalData
Dr Stuart Ward, head of business analysis at IDBS, discusses why organisations should be considering transitioning to cloud-based software and technologies and some of the important things they should keep in mind.
Bryan Plaster, VP Customer Services at Trifacta, tells us more about how establishing a centre of excellence (CoE) for data analytics can help organisations accelerate research & development (R&D).
We have now passed the six month point before the Falsified Medicines Directive (FMD) comes into force. In this online exclusive, Mark Davison, senior operations director, rfxcel insists you ACT NOW! Here are six short reflections.
